All News

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

The study will assess the safety and efficacy of a next-generation COVID-19 vaccine via nasal spray and inhalation.

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

Your daily dose of the clinical news you may have missed.

William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.

Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.

Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

Your daily dose of the clinical news you may have missed.

Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.

Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.

The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.

Your daily dose of the clinical news you may have missed.

Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.